The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer

Prostate

Volumn 75, Issue 9, 2015, Pages 897-906

  Graff, Rebecca E ^a,b   Pettersson, Andreas ^a   Lis, Rosina T ^c,d   Dupre, Natalie ^a   Jordahl, Kristina M ^a   Nuttall, Elizabeth ^a   Rider, Jennifer R ^a,e   Fiorentino, Michelangelo ^a,d,f   Sesso, Howard D ^a,e   Kenfield, Stacey A ^a,e,g   Loda, Massimo ^c,d   Giovannucci, Edward L ^a,e   Rosner, Bernard ^a,e   Nguyen, Paul L ^e   Sweeney, Christopher J ^e   Mucci, Lorelei A ^a,e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

androgen deprivation therapy; gene fusion; prognosis; prostate cancer; TMPRSS2:ERG

Indexed keywords

MEMBRANE PROTEIN; TMPRSS2 PROTEIN; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; ANTIANDROGEN; ONCOPROTEIN; TMPRSS2-ERG FUSION PROTEIN, HUMAN;

ADOLESCENT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; AGED; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; QUESTIONNAIRE; SURVIVAL;

AGED; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NONSTEROIDAL ANTI-ANDROGENS; ONCOGENE PROTEINS, FUSION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVEYS AND QUESTIONNAIRES; SURVIVAL ANALYSIS;

EID: 84929999835     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22973     Document Type: Article

References (24)

1. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI,. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-1605.
2. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A,. EAU guidelines on prostate cancer. part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Actas Urol Esp 2011; 59: 572-583.
3. De Sy WA, De Wilde P, De Meyer JM, Casselman J, Desmet R, Renders G, Schelfhout W,. Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy. Acta Urol Belg 1988; 56: 581-588.
4. Moreau JP, Delavault P, Blumberg J,. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy. Clin Ther 2006; 28: 1485-1508.
5. Tomlins S, Rhodes D, Perner S, Dhanasekaran S, Mehra R, Sun X, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie J, Shah R, Pienta K, Rubin M, Chinnaiyan A,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
6. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA,. ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol 2009; 56: 275-286.
7. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, Stanimirovic A, Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA, Seth A,. Expression of the TMPRS S2: ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007; 97: 1690-1695.
8. Seth A, Watson DK,. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005; 41: 2462-2478.
9. Boormans JL, Hermans KG, Made AC, van Leenders GJ, Wildhagen MF, Collette L, Schroder FH, Trapman J, Verhagen PC,. Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naive, node-positive prostate cancer. Eur Urol 2010; 57: 830-835.
10. Attard G, Jameson C, Moreira J, Flohr P, Parker C, Dearnaley D, Cooper CS, de Bono JS,. Hormone-sensitive prostate cancer: A case of ETS gene fusion heterogeneity. J Clin Pathol 2009; 62: 373-376.
11. Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA, Tang H, Munz JM, Kosari F, Vasmatzis G,. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status. Cancer Res 2010; 70: 8994-9002.
12. Leinonen K, Tolonen T, Bracken H, Stenman U, Tammela T, Saramaki O, Visakorpi T,. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 2010; 16: 2845-2851.
13. Hennekens CH, Eberlein K,. A randomized trial of aspirin and beta-carotene among U.S. physicians. Prev Med 1985; 14: 165-168.
14. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Sesso HD, Buring JEVitamins,. C in the prevention of prostate and total cancer in men: The Physicians' Health Study II randomized controlled trial. JAMA 2009; 301: 52-62.
15. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA,. Gleason score and lethal prostate cancer: Does 3+4=4+3. J Clin Oncol 2009; 27: 3459-3464.
16. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M, Mucci LA,. The TMPRS S2: ERG rearrangement, ERG expression, and prostate cancer outcomes: A cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012; 21: 1497-1509.
17. Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM, Netto GJ,. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol 2011; 35: 1014-1020.
18. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA,. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12: 590-598.
19. van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B, Trapman J,. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: Implications for pathological practice. Mod Pathol 2011; 24: 1128-1138.
20. Bastus NC, Boyd LK, Mao X, Stankiewicz E, Kudahetti SC, Oliver RT, Berney DM, Lu YJ,. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 2010; 70: 9544-9548.
21. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, Rosenfeld MG,. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009; 139: 1069-1083.
22. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS,. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 2912-2918.
23. Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI,. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011; 60: 897-904.
24. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.